Addition of exogenous sodium palmitate increases the IAPP/insulin mRNA ratio via GPR40 in human EndoC-βH1 cells

References

• U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249–58.
   PubMed Web of Science ®Google Scholar
• Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–S5.
   PubMed Web of Science ®Google Scholar
• Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–43.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 1999;48:241–53.
   PubMed Web of Science ®Google Scholar
• Clark A. Islet amyloid and type 2 diabetes. Diabet Med. 1989;6:561–7.
   PubMed Web of Science ®Google Scholar
• Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia. 1989;32:240–4.
   PubMed Web of Science ®Google Scholar
• Fehmann HC, Weber V, Goke R, Goke B, Arnold R. Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett. 1990;262:279–81.
   PubMed Web of Science ®Google Scholar
• Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1992;15:89–96.
   PubMed Web of Science ®Google Scholar
• Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE. Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol. 1998;275:E785–91.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes. 1998;47:640–5.
   PubMed Web of Science ®Google Scholar
• Knowles NG, Landchild MA, Fujimoto WY, Kahn SE. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2002;25:292–7.
   PubMed Web of Science ®Google Scholar
• Novials A, Sarri Y, Casamitjana R, Rivera F, Gomis R. Regulation of islet amyloid polypeptide in human pancreatic islets. Diabetes. 1993;42:1514–19.
   PubMed Web of Science ®Google Scholar
• Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology. 2008;149:5423–31.
   PubMed Web of Science ®Google Scholar
• Udayasankar J, Kodama K, Hull RL, Zraika S, Aston-Mourney K, Subramanian SL, et al. Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia. 2009;52:145–53.
   PubMed Web of Science ®Google Scholar
• Mulder H, Martensson H, Sundler F, Ahren B. Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism. 2000;49:1518–22.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Leckstrom A, Ma Z, Westermark P. Increased release of IAPP in response to long-term high fat intake in mice. Horm Metab Res. 1998;30:256–8.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med. 2000;6:998–1007.
   PubMed Web of Science ®Google Scholar
• Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795–826.
   PubMed Web of Science ®Google Scholar
• Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897–904.
   PubMed Web of Science ®Google Scholar
• Skeldon AM, Faraj M, Saleh M. Caspases and inflammasomes in metabolic inflammation. Immunol Cell Biol. 2014;92:304–13.
   PubMed Web of Science ®Google Scholar
• Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194–204.
   PubMed Web of Science ®Google Scholar
• Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P, et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest. 2011;121:3589–97.
   PubMed Web of Science ®Google Scholar
• Qi D, Cai K, Wang O, Li Z, Chen J, Deng B, et al. Fatty acids induce amylin expression and secretion by pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2010;298:E99–107.
   PubMed Web of Science ®Google Scholar
• Andersson LE, Valtat B, Bagge A, Sharoyko VV, Nicholls DG, Ravassard P, et al. Characterization of stimulus-secretion coupling in the human pancreatic EndoC-betaH1 beta cell line. PLoS One. 2015;10:e0120879.
   PubMed Web of Science ®Google Scholar
• Gurgul-Convey E, Kaminski MT, Lenzen S. Physiological characterization of the human EndoC-betaH1 beta-cell line. Biochem Biophys Res Commun. 2015;464:13–19.
   PubMed Web of Science ®Google Scholar
• Hatanaka M, Maier B, Sims EK, Templin AT, Kulkarni RN, Evans-Molina C, et al. Palmitate induces mRNA translation and increases ER protein load in islet beta-cells via activation of the mammalian target of rapamycin pathway. Diabetes. 2014;63:3404–15.
   PubMed Web of Science ®Google Scholar
• Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab. 2013;24:398–407.
   PubMed Web of Science ®Google Scholar
• Mancini AD, Poitout V. [Membrane fatty acid receptors in the beta-cell: novel therapeutic targets for type 2 diabetes]. Med Sci (Paris). 2013;29:715–21.
   PubMed Web of Science ®Google Scholar
• Wu J, Sun P, Zhang X, Liu H, Jiang H, Zhu W, et al. Inhibition of GPR40 protects MIN6 beta cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 2012;113:1152–8.
   PubMed Web of Science ®Google Scholar
• Sun P, Wang T, Zhou Y, Liu H, Jiang H, Zhu W, et al. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice. PLoS One. 2013;8:e66744.
   PubMed Web of Science ®Google Scholar
• Natalicchio A, Labarbuta R, Tortosa F, Biondi G, Marrano N, Peschechera A, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 2013;56:2456–66.
   PubMed Web of Science ®Google Scholar
• Poitout V, Hagman D, Stein R, Artner I, Robertson RP, Harmon JS. Regulation of the insulin gene by glucose and fatty acids. J Nutr. 2006;136:873–6.
   PubMed Web of Science ®Google Scholar
• Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996;392:77–80.
   PubMed Web of Science ®Google Scholar
• Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2. J Biol Chem. 2014;289:11807–15.
   PubMed Web of Science ®Google Scholar
• Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92:29–39.
   PubMed Web of Science ®Google Scholar